Get the Stockscreener App
0.206
4.50%
-0.0097
After Hours:
.20
-0.006
-2.91%
Mangoceuticals Inc stock is traded at $0.206, with a volume of 913.64K.
It is down -4.50% in the last 24 hours and down -25.90% over the past month.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
See More
Previous Close:
$0.2157
Open:
$0.207
24h Volume:
913.64K
Relative Volume:
0.22
Market Cap:
$6.57M
Revenue:
-
Net Income/Loss:
$-7.32M
P/E Ratio:
-0.4706
EPS:
-0.4377
Net Cash Flow:
$-5.99M
1W Performance:
-5.98%
1M Performance:
-25.90%
6M Performance:
-23.42%
1Y Performance:
-69.93%
1-Day Range:
$0.2001
$0.2345
1-Week Range:
$0.189
$0.2345
52-Week Range:
$0.143
$1.12
Mangoceuticals Inc Stock (MGRX) Company Profile
Name
Mangoceuticals Inc
Sector
Industry
Phone
(833) 626-4679
Address
15110 DALLAS PKWY, SUITE 600, DALLAS
Mangoceuticals Inc Stock (MGRX) Latest News
Mangoceuticals announces 1-for-15 reverse stock split - MSN
MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK - GlobeNewswire
Mangoceuticals Inc’s Market Journey: Closing Weak at 0.22, Down -0.64 - The Dwinnex
Get in on Mangoceuticals Inc’s (MGRX) buy-in window today! - SETE News
Men's health company MangoRx launches weight loss drugs - The Business Journals
How analysts predict Mangoceuticals Inc (MGRX) will perform this quarter? - US Post News
MGRX’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
An Analysis of Mangoceuticals Inc (MGRX)’s Potential Price Growth - Knox Daily
Trading Day Review: Mangoceuticals Inc (MGRX) Loses Momentum, Closing at 0.24 - The Dwinnex
Mangoceuticals (NASDAQ:MGRX) Trading Down 11.3% – Should You Sell? - Defense World
Mangoceuticals launches oral weight loss tablet TRIM By Investing.com - Investing.com South Africa
Mangoceuticals issues equity for consulting and marketing services By Investing.com - Investing.com Australia
Mangoceuticals launches oral weight loss tablet TRIM By Investing.com - Investing.com Australia
Mangoceuticals launches oral weight loss tablet TRIM - Investing.com
Mangoceuticals launches oral weight loss tablet TRIM By Investing.com - Investing.com UK
MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions - GlobeNewswire
MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions - ForexTV.com
You might want to take a look at Mangoceuticals Inc (MGRX) now - SETE News
Mangoceuticals issues equity for consulting and marketing services - Investing.com India
Mangoceuticals Inc. (NASDAQ:MGRX) Stock Soars After Launch of Oral Semaglutide for Advanced Weight Loss Treatment - DRP Journal
Mangoceuticals issues equity for consulting and marketing services - Investing.com
Mangoceuticals issues equity for consulting and marketing services By Investing.com - Investing.com UK
Market cap of Mangoceuticals Inc [MGRX] reaches 8.93M – now what? - The DBT News
Mangoceuticals Inc (NASDAQ: MGRX) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
Mangoceuticals Inc’s latest rating changes from various analysts - Knox Daily
Healthcare Shares Rise Following Product Availability Announcement - MSN
MangoRx launches oral weight loss treatment Slim By Investing.com - Investing.com Australia
MangoRx launches oral weight loss treatment Slim By Investing.com - Investing.com South Africa
Charting the Course: Mangoceuticals Inc’s MGRX Stock Prospects - The InvestChronicle
TSX Diversified Banks EW Index (TXDE) QuotePress Release - The Globe and Mail
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
S&P GSCI Index (GNX) QuotePress Release - The Globe and Mail
MangoRx launches oral weight loss treatment Slim By Investing.com - Investing.com Canada
MangoRx launches oral weight loss treatment Slim - Investing.com India
MangoRx launches oral weight loss treatment Slim - Investing.com
MangoRx Addresses $49.3 Billion Global GLP-1 Market With - GlobeNewswire
Mangoceuticals launches oral semaglutide for advanced weight loss treatment - TipRanks
Mangoceuticals (NASDAQ:MGRX) Trading Down 3.3% - Defense World
Erectile Dysfunction Treatment Market Expected to Expand at - openPR
A year in review: Mangoceuticals Inc (MGRX)’s performance in the last year - US Post News
Balance Sheet Breakdown: Mangoceuticals Inc (MGRX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Mangoceuticals Inc (MGRX) Stock: A Year of Declines and Increases - The InvestChronicle
Mangoceuticals Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
Market Momentum: Mangoceuticals Inc (MGRX) Registers a -15.70 Decrease, Closing at 0.22 - The Dwinnex
Mangoceuticals issues equity, CEO gets raised car allowance - Investing.com
Mangoceuticals issues equity, CEO gets raised car allowance By Investing.com - Investing.com South Africa
Mangoceuticals Raises Capital and Boosts CEO Perks - TipRanks
Mangoceuticals Second Quarter 2024 Earnings: US$0.092 loss per share (vs US$0.14 loss in 2Q 2023) - Yahoo Finance
Mangoceuticals (NASDAQ:MGRX) Stock Price Down 2.7% - Defense World
MangoRx Reports 1,685% Increase in Shareholders’ Equity - GlobeNewswire
MangoRx Reports 1,685% Increase in Shareholders’ Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024 - StockTitan
Mangoceuticals Inc Stock (MGRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mangoceuticals Inc Stock (MGRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hamilton Alex P. | Director |
Jun 25 '24 |
Sale |
0.31 |
16,574 |
5,138 |
158,426 |
0.07%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):